Written by Elizabeth Smyth MD Written by Somnath Mukherjee MD, MRCP, FRCR, FRCP

Operable gastrooesophageal adenocarcinoma (GOA) is treated with multimodality therapy which is curative in <50% of patients. Patients in the UK with o…

Perioperative chemoimmunotherapy [i.e. chemotherapy plus immune checkpoint inhibitor (ICI) (ChT–ICI)] is an investigational treatment for operable gastroesophageal adenocarcinoma (GEA) with unclear ou...

In this Review, Sharma and colleagues describe the current landscape of combination therapies and discuss requirements for the development of effective combination strategies.

Gupta et al. demonstrate that high EGFR expression mediates resistance to HER2 antibody drug conjugates (ADCs) including trastuzumab deruxtecan (T-DXd) by limiting HER2/ADC internalization. The additi...

Jessie Elliott, FRCS, PhD, Trinity St. James’s Cancer Institute, Dublin, Ireland, discusses the long-term survivorship concerns of patients with esophageal...